BPC-157 / TB-500 research overview

Compound identity and classification

BPC-157 / TB-500 is classified as: Co-formulation of two synthetic peptides.

This material contains two separately synthesized peptides — BPC-157, a pentadecapeptide, and TB-500, the active fragment of thymosin β4 — co-lyophilized in one vial. Identity and purity are documented per constituent; no combined purity figure is generated.

General research background

The individual peptides each have their own preclinical literature in tissue and cellular models. Literature specific to the combination is limited, and no additive or synergistic effect should be inferred from co-formulation.

Molecular and biological pathways under investigation

Two distinct pathway sets are studied: growth-factor and angiogenesis-related signaling associated with BPC-157 research, and actin-sequestration and cell-migration processes associated with thymosin β4 fragment research.

Areas of laboratory research

Reported laboratory work with this material clusters into the following areas. Listing an area describes where research activity exists, not an established result.

• Constituent-resolved analytical verification
• Cell migration and scratch-wound assays
• Angiogenesis and endothelial tube-formation models
• Comparative studies against each constituent alone

Analytical documentation

ATMI Labs publishes the identity and purity documentation supplied for each released lot. Any purity figure shown comes from the report filed for that specific batch rather than from a general catalog claim.

Research limitations

Published work involving BPC-157 / TB-500 is largely confined to in vitro systems and preclinical animal models. Findings in those systems do not establish effects in humans, and model-to-model variability in preparation, vehicle, and endpoint selection limits direct comparison between studies.

Analytical purity describes the material, not biological activity. Laboratories should design their own controls, and treat any pathway description as a hypothesis under investigation rather than an established result.

Handling and laboratory considerations

Lyophilized research materials are handled as temperature-sensitive laboratory chemicals. Storage temperature, reconstitution solvent, container choice, and stability windows are determined by the receiving laboratory's written protocol.

Every ATMI Labs lot is released with batch documentation so identity and purity figures used in a study can be traced back to the specific lot in hand.

• Confirm the lot identifier on the vial label against the published quality record.
• Record lot, strength, and receipt date in the laboratory inventory before use.
• Follow institutional handling, labeling, and disposal procedures for research chemicals.

References and scientific sources

ATMI Labs does not summarize or reinterpret individual studies on this page. Laboratories designing work with this material are expected to consult the primary literature directly.

• PubMed / MEDLINE (National Library of Medicine) for peer-reviewed primary literature.
• PubChem and ChEMBL for chemical identity, structure, and physicochemical records.
• UniProt for sequence and receptor/target annotation where a protein target applies.
• The lot-specific quality record published by ATMI Labs for analytical identity and purity.

Research use scope

BPC-157 / TB-500 supplied by ATMI Labs is sold exclusively for laboratory research and analytical purposes. It is not a drug, supplement, cosmetic, or food, and it is not intended for human or veterinary use.

Nothing on this page describes therapeutic use, dosing, or clinical outcomes. Literature referenced in general terms describes laboratory and preclinical model systems only.